ValiRx plc (VAL) AI Stock Analysis

• Market Cap: £2.38M
• Dividend Yield: N/A
• Average Volume (3M): 1.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: 418.49%
• EPS Growth: 27.86%
• Country: UK
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 742,721,070
• 10 Day Avg. Volume: 510,641
• 30 Day Avg. Volume: 1,099,814
• PEG Ratio: 0.02
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 20.52
• P/FCF Ratio: -0.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: 0.33p ▼(-7.22% Downside)

ValiRx plc's overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and reliance on external financing. The technical analysis suggests a bearish trend, with some potential for upward movement. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.

Positive Factors

Revenue Growth

Despite a low base, ValiRx's revenue growth indicates potential for future expansion as products progress through clinical trials and achieve regulatory approvals.

Equity Position

A strong equity position provides ValiRx with a buffer against financial volatility, supporting long-term operational stability and potential for future investment.

Proprietary Technology Platforms

Proprietary technology platforms offer ValiRx a competitive edge in developing innovative cancer therapies, potentially leading to successful drug commercialization.

Negative Factors

Negative Profitability Margins

Negative profitability margins highlight operational inefficiencies and high costs, which could hinder long-term financial sustainability unless addressed.

Cash Flow Challenges

Reliance on external financing for cash flow raises concerns about ValiRx's ability to sustain operations without consistent revenue generation.

Negative Free Cash Flow

Negative free cash flow indicates that ValiRx is spending more than it earns, which could limit its ability to invest in growth and innovation over time.

ValiRx plc Business Overview & Revenue Model

Company Description

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

How the Company Makes Money

ValiRx generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model includes potential licensing agreements, partnerships with larger pharmaceutical companies, and grants for research and development. Key revenue streams may arise from milestone payments as products progress through clinical trials and achieve regulatory approvals, as well as royalties from sales of successfully commercialized drugs. Additionally, ValiRx may benefit from collaborations with academic institutions and other biotech firms that can provide funding and resources for its research initiatives.

ValiRx plc Financial Statement Overview

Summary

ValiRx plc is facing substantial financial challenges typical of a biotech firm in its growth phase, with ongoing net losses and reliance on external financing. While equity is strong, profitability and cash flow constraints pose significant risks. The company needs to improve operational efficiency and revenue generation to enhance financial stability and investor confidence.

Income Statement

ValiRx plc exhibits a challenging income statement with negative profitability margins. The gross profit margin is negative due to the cost of revenue exceeding total revenue, and the net profit margin is significantly negative, indicating substantial losses relative to revenue. Revenue growth is present, but the base is very low, which makes the growth percentage less impactful. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high operating expenses.

Balance Sheet

The balance sheet shows a relatively solid equity position compared to liabilities, with a high equity ratio. However, the debt-to-equity ratio is low, indicating minimal leverage, which can be a double-edged sword in biotech if additional funding is needed. Return on equity is negative, driven by continuous net losses, signaling the need for improved profitability to enhance shareholder value.

Cash Flow

Cash flow statements reveal negative free cash flow, though there is a slight improvement in operating cash flow. The company relies heavily on financing activities for cash, which may not be sustainable long-term. The operating cash flow to net income ratio is negative, suggesting cash flow challenges in converting sales into cash. Free cash flow growth rates are negative, reflecting ongoing capital expenditure needs without sufficient revenue support.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.77K	9.60K	0.00	0.00	0.00
Gross Profit	-217.22K	-246.04K	-224.27K	-228.79K	-229.50K
EBITDA	-1.86M	-2.04M	-2.37M	-1.45M	-1.31M
Net Income	-1.92M	-2.04M	-2.41M	-1.55M	-1.47M
Balance Sheet
Total Assets	4.26M	3.13M	3.98M	3.52M	4.94M
Cash, Cash Equivalents and Short-Term Investments	1.56M	174.68K	1.14M	593.67K	1.85M
Total Debt	11.86K	22.07K	37.71K	58.72K	71.06K
Total Liabilities	346.41K	226.51K	149.65K	109.56K	182.40K
Stockholders Equity	4.32M	3.22M	4.05M	3.60M	4.91M
Cash Flow
Free Cash Flow	-1.62M	-2.08M	-1.71M	-1.26M	-2.00M
Operating Cash Flow	-1.58M	-1.77M	-1.71M	-1.26M	-1.91M
Investing Cash Flow	-38.16K	-306.18K	0.00	0.00	-91.29K
Financing Cash Flow	3.00M	1.12M	2.26M	7.34K	3.85M

ValiRx plc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Neutral. The current price of 0.36 is above the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.36, and below the 200-day MA of 0.52, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.88 is Neutral, neither overbought nor oversold. The STOCH value of 48.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:VAL.

ValiRx plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FAB	50 Neutral	£21.88M	-12.15	-164.37%	―	-11.43%	23.40%
TCF	49 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
NFX	42 Neutral	£5.59M	-0.63	-153.80%	―	―	-616.67%
VAL	41 Neutral	£2.38M	-0.24	―	―	418.49%	27.86%
OBD	40 Underperform	£10.94M	-0.09	-333.59%	―	45.22%	55.71%

ValiRx plc Corporate Events

ValiRx Advances with New Equity and Warrant Issuance Post-General Meeting

ValiRx plc announced the successful passing of all resolutions at its recent General Meeting, paving the way for the issuance of new equity and warrants as part of its fundraising efforts. The company plans to admit 256,067,800 new shares to trading on AIM, with the issuance of 368,372,400 fundraising warrants and 16,036,120 broker warrants, which are exercisable until the third anniversary of the admission. This strategic move is expected to bolster ValiRx’s financial position, enabling further investment in its pipeline of cancer therapeutics and women’s health products, potentially enhancing its market position and delivering value to stakeholders.

ValiRx PLC Announces Fundraising to Boost Cancer and Women’s Health Research

ValiRx PLC has announced the posting of a circular and notice for a General Meeting to discuss a fundraising initiative aimed at raising approximately £902,000. The funds will support research and development efforts, including the preclinical development of Cytolytix and VAL201 2.0, as well as operational costs. This fundraising effort is part of ValiRx’s strategy to enhance the translation of novel research into clinical applications, focusing on oncology and women’s health. The issuance of new shares and warrants will significantly increase the company’s share capital, impacting its market positioning and providing resources for future growth.

ValiRx PLC Raises £902,000 Through Successful Fundraising

ValiRx PLC has successfully raised approximately £902,000 through its WRAP Retail Offer and other fundraising activities, issuing new ordinary shares at a price of 0.25 pence per share. This capital injection is expected to support the company’s ongoing operations and strategic initiatives, potentially strengthening its position in the life sciences industry and providing value to its stakeholders.

ValiRx Plc Raises £902,000 Through Successful WRAP Retail Offer

ValiRx Plc announced the successful completion of its WRAP Retail Offer, raising approximately £152,000 through the issuance of new ordinary shares. Combined with previous fundraising efforts, the company has secured a total of £902,000. The new shares are expected to commence trading on AIM by 21 November 2025, subject to the approval of Fundraising Resolutions at the General Meeting. This fundraising effort is anticipated to bolster ValiRx’s financial position and support its strategic initiatives in the life sciences sector.

ValiRx Plc Launches £300,000 Retail Offer to Boost Cancer Therapeutics Development

ValiRx Plc has announced a retail offer via the Winterflood Retail Access Platform to raise up to £300,000 through the issuance of new ordinary shares and warrants. This initiative is part of a broader fundraising effort, where the company has conditionally raised £750,000 through a placing and subscription of new shares. The funds raised will support the company’s ongoing projects and operations. The offer is open to eligible retail investors in the UK and is expected to close on 3 November 2025, with the results announced shortly thereafter. This move aims to strengthen ValiRx’s financial position and expand its retail shareholder base.

ValiRx PLC Launches £1.05 Million Fundraising to Boost Cancer and Women’s Health Initiatives

ValiRx PLC has announced a fundraising initiative to raise up to £1,050,000 through a combination of firm and conditional placings, a WRAP Retail Offer, and direct subscriptions by company directors. The initiative, which includes the issuance of new shares and fundraising warrants, aims to support the company’s operations in a challenging funding environment. The funds will be used to expand ValiRx’s evaluation pipeline and progress existing projects, enhancing its strategic position in the oncology and women’s health sectors.

ValiRx PLC Advances Cancer Therapeutics with Strategic Partnerships and Innovations

ValiRx PLC announced significant progress in its subsidiary Inaphaea Limited, including the completion of a service contract phase with Amply Discovery Limited and a substantial UKRI grant for developing an in-silico spheroid modeling platform. These advancements, alongside collaborations with Nottingham Health Trust and TwinEdge BioScience, enhance ValiRx’s capabilities in drug development and patient-derived cell modeling. Additionally, ValiRx’s agreement with Apis Assay Technologies Ltd to evaluate HER2 targeting technology and recent academic appointments for key personnel underscore the company’s commitment to innovation and collaboration in cancer therapeutics.

ValiRx Reports Strategic Advancements and Cost Efficiency in H1 2025

ValiRx Plc has released its unaudited half-yearly report for the period ending June 30, 2025, highlighting strategic and operational advancements, including new partnerships and agreements aimed at enhancing its cancer therapeutic development. The company has undergone a strategic review to improve operational efficiency, resulting in cost savings and a leaner team structure. Despite challenging trading conditions and funding uncertainties, ValiRx has secured multiple pump-priming awards and is exploring further grant opportunities. The company is also focusing on developing its Inaphaea Biolabs subsidiary and enhancing its capabilities in new approach methodologies, aligning with regulatory trends to phase out animal testing.

ValiRx Advances Cancer Therapeutics with Digital Twin Collaboration

ValiRx’s subsidiary, Inaphaea Limited, has entered a collaboration with TwinEdge Bioscience to enhance cancer therapy development through digital ‘patient avatars,’ leveraging AI and computational biology. This partnership aims to transform drug development by creating one of the largest populations of digital twins, potentially reducing clinical trial costs and improving patient-drug matching. Inaphaea also advances its capabilities with agreements for new cancer cell models and the 3K Screen program, which identified promising drug candidates for further testing and commercial opportunities.